Cargando…

Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers

INTRODUCTION: In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged ≥ 65 years, wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sacco, Patricia, Myers, Kelley, Poulos, Christine, Sweeney, Carolyn, Hollis, Kelly, Snow, Vincenza, Vietri, Jeffrey T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856229/ https://www.ncbi.nlm.nih.gov/pubmed/31549313 http://dx.doi.org/10.1007/s40121-019-00266-5

Ejemplares similares

06. United States Healthcare Provider Preferences for Adult Pneumococcal Vaccine Recommendations
por: Vietri, Jeffrey, et al.
Publicado: (2021)

1740. Healthcare Providers’ Preferences for Pediatric Pneumococcal Vaccination Recommendations in the United States
por: Vietri, Jeffrey T, et al.
Publicado: (2023)

Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
por: McLaughlin, John, et al.
Publicado: (2017)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
por: McLaughlin, John M., et al.
Publicado: (2019)

Health Care Provider Knowledge and Attitudes Regarding Adult Pneumococcal Conjugate Vaccine Recommendations — United States, September 28–October 10, 2022
por: Kahn, Rebecca, et al.
Publicado: (2023)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment
por: Poulos, Christine, et al.
Publicado: (2015)

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
por: Furlan, Roberto, et al.
Publicado: (2015)

PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE
por: Poulos, Christine, et al.
Publicado: (2018)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
por: Vietri, Jeffrey, et al.
Publicado: (2019)

Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States
por: Noharet-Koenig, Roxane, et al.
Publicado: (2023)

ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
Publicado: (2023)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

1438. Uptake of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Adults Aged 19–64 Years: A Kaplan–Meier Approach
por: Vietri, Jeffrey, et al.
Publicado: (2018)

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
por: Kobayashi, Miwako, et al.
Publicado: (2023)

Residual Effects of Sleep Medications Are Commonly Reported and Associated with Impaired Patient-Reported Outcomes among Insomnia Patients in the United States
por: Fitzgerald, Timothy, et al.
Publicado: (2015)

2656. Eliciting Preferences for Zoster Vaccination in US Adults Aged 50 Years and Older
por: Patterson, Brandon J, et al.
Publicado: (2019)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Current Recommendations for Pneumococcal Vaccination of Children and Adults
por: Fakhraei, Hossein, et al.
Publicado: (2015)

Recommendation to Take a Holistic View of the Dynamic Pathogenic Pneumococcal Environment
por: Izurieta, Patricia, et al.
Publicado: (2022)

Provider recommendation for HPV vaccination across Hispanic/Latinx subgroups in the United States
por: Reiter, Paul L., et al.
Publicado: (2020)

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Kobayashi, Miwako, et al.
Publicado: (2022)

Immunization with Attenuated Pneumococcal Strains Provides Protection against Pneumococcal Colonization in Humans
por: Narciso, Ana Rita, et al.
Publicado: (2023)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

180. Impact of Pneumococcal Conjugative Vaccine on Antibiotic Resistant Invasive Pneumococcal Disease in the United States
por: Bajema, Kristina, et al.
Publicado: (2020)

Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Chen, Jieling, et al.
Publicado: (2014)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
por: Wasserman, Matt, et al.
Publicado: (2021)

2727. Numbers Needed to Vaccinate for Prevention of Adult Pneumonia with Pneumococcal Conjugate Vaccine: Which Values Should Determine Policy?
por: Gessner, Bradford D, et al.
Publicado: (2019)

Healthcare Providers’ Adherence to Recommended Pneumococcal and Influenza Vaccination in Patients Discharged with Respiratory Diseases from General Medical Wards
por: Alshehri, Amani, et al.
Publicado: (2023)

Access to later abortion in the United States during COVID-19: challenges and recommendations from providers, advocates, and researchers
por: Ruggiero, Samantha, et al.
Publicado: (2020)

A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States
por: McLaughlin, John M, et al.
Publicado: (2015)

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Kobayashi, Miwako, et al.
Publicado: (2022)

1105 Chronic Kidney Disease and Invasive Pneumococcal Disease in Adults
por: Baxter, Roger, et al.
Publicado: (2014)

Models of school recess for combatting overweight in the United States
por: Kahan, David, et al.
Publicado: (2022)

1097 Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Yang, H. Keri, et al.
Publicado: (2014)

Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines
por: Torres, Antoni
Publicado: (2016)

Pneumococcal Vaccination Provides Substantial Value for Money for Canadians
por: Peloquin, Francois, et al.
Publicado: (2017)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7eek75s8p8fdnogudafi4ba83o